Short answer
Praxis Precision Medicines, Inc. (PRAX) filed an 8-K current report with the SEC on April 14, 2026 reporting Item 8.01 (Other Events). FDA acceptance begins formal review of ulixacaltamide HCl for essential tremor in adults.
Praxis Precision Medicines, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- FDA acceptance begins formal review of ulixacaltamide HCl for essential tremor in adults
- PDUFA target action date: January 29, 2027
- No FDA advisory committee meeting planned, reducing a potential review milestone
- Approval could create a regulatory catalyst for Praxis’ essential-tremor program
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Praxis Precision Medicines, Inc. 8-K filings
Get the next PRAX 8-K as it lands
Follow PRAX for push alerts, or ask the research agent what this filing means.